Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Summit Therapeutics (SMMT) Change in Intangibles (2019 - 2020)

Summit Therapeutics' Change in Intangibles history spans 2 years, with the latest figure at -$168000.0 for Q3 2020.

For Q3 2020, Change in Intangibles changed N/A year-over-year to -$168000.0; the TTM value through Jun 2021 reached -$168000.0, changed N/A, while the annual FY2019 figure was $136000.0, N/A changed from the prior year.
Change in Intangibles reached -$168000.0 in Q3 2020 per SMMT's latest filing, down from $4000.0 in the prior quarter.
In the past five years, Change in Intangibles ranged from a high of $164000.0 in Q1 2020 to a low of -$168000.0 in Q3 2020.